Beam Therapeutics (BEAM) Competitors $17.86 -0.44 (-2.40%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$18.10 +0.25 (+1.37%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BEAM vs. CRSP, DNLI, EDIT, NTLA, TWST, VCYT, BPMC, ROIV, LEGN, and RGCShould you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Twist Bioscience (TWST), Veracyte (VCYT), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Legend Biotech (LEGN), and Regencell Bioscience (RGC). Beam Therapeutics vs. Its Competitors CRISPR Therapeutics Denali Therapeutics Editas Medicine Intellia Therapeutics Twist Bioscience Veracyte Blueprint Medicines Roivant Sciences Legend Biotech Regencell Bioscience CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation. Which has stronger valuation and earnings, CRSP or BEAM? CRISPR Therapeutics has higher earnings, but lower revenue than Beam Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$37.31M136.41-$366.25M-$5.43-10.31Beam Therapeutics$63.52M28.44-$376.74M-$4.50-3.97 Which has more volatility & risk, CRSP or BEAM? CRISPR Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500. Does the media refer more to CRSP or BEAM? In the previous week, CRISPR Therapeutics had 18 more articles in the media than Beam Therapeutics. MarketBeat recorded 37 mentions for CRISPR Therapeutics and 19 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.57 beat CRISPR Therapeutics' score of 0.53 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 8 Very Positive mention(s) 9 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Is CRSP or BEAM more profitable? Beam Therapeutics has a net margin of -661.31% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,229.43% -20.05% -17.09% Beam Therapeutics -661.31%-43.15%-31.06% Do analysts recommend CRSP or BEAM? CRISPR Therapeutics presently has a consensus price target of $71.60, indicating a potential upside of 27.95%. Beam Therapeutics has a consensus price target of $48.45, indicating a potential upside of 171.30%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.50Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.07 Do insiders and institutionals have more ownership in CRSP or BEAM? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryBeam Therapeutics beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks. Get Beam Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAM vs. The Competition Export to ExcelMetricBeam TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$2.98B$5.48B$9.56BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-3.9717.9729.9325.14Price / Sales28.44179.55375.2276.13Price / CashN/A41.8335.9458.58Price / Book1.737.238.105.59Net Income-$376.74M-$54.43M$3.26B$265.48M7 Day Performance-5.15%0.22%0.68%1.22%1 Month Performance-12.02%5.59%2.45%0.39%1 Year Performance-28.30%9.98%27.72%23.47% Beam Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEAMBeam Therapeutics2.755 of 5 stars$17.86-2.4%$48.45+171.3%-27.0%$1.85B$63.52M-3.97510Earnings ReportAnalyst ForecastAnalyst RevisionCRSPCRISPR Therapeutics3.6785 of 5 stars$63.75-1.6%$71.31+11.9%+18.4%$5.51B$35M-14.10460Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionDNLIDenali Therapeutics4.1234 of 5 stars$13.63-0.3%$33.71+147.4%-34.4%$1.98BN/A-5.10430EDITEditas Medicine4.24 of 5 stars$2.96-6.0%$4.70+58.8%-39.4%$247.79M$35.84M-0.97230NTLAIntellia Therapeutics4.2328 of 5 stars$13.11-3.6%$33.37+154.5%-46.2%$1.36B$45.57M-2.51600News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastTWSTTwist Bioscience3.5447 of 5 stars$36.53+1.5%$50.40+38.0%-43.9%$2.19B$312.97M-11.24990Earnings ReportAnalyst RevisionVCYTVeracyte2.6991 of 5 stars$25.02-0.9%$40.90+63.5%+2.3%$1.96B$463.39M61.03790Trending NewsGap UpHigh Trading VolumeBPMCBlueprint Medicines0.6943 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.3659 of 5 stars$11.35-1.7%$16.50+45.4%+13.6%$7.72B$29.05M-45.40860Upcoming EarningsLEGNLegend Biotech3.8544 of 5 stars$41.51-4.3%$73.33+76.7%-32.0%$7.63B$627.24M-70.352,609News CoveragePositive NewsUpcoming EarningsAnalyst RevisionRGCRegencell Bioscience0.1559 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010Positive News Related Companies and Tools Related Companies CRSP Alternatives DNLI Alternatives EDIT Alternatives NTLA Alternatives TWST Alternatives VCYT Alternatives BPMC Alternatives ROIV Alternatives LEGN Alternatives RGC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BEAM) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BEAM Stock Alerts